Please login to the form below

Not currently logged in
Email:
Password:

Exjade

This page shows the latest Exjade news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

The committee also recommended a new generic from Mylan of Novartis’ Exjade (deferasirox), which is used to treat chronic iron overload due to blood transfusions in patients with beta thalassaemia, ... Exjade made sales of more than $1bn last year. The

Latest news

  • Novartis close to US bribery settlement Novartis close to US bribery settlement

    In 2015, Novartis paid $390m to settle claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.

  • Novartis kicks back against US corruption charges Novartis kicks back against US corruption charges

    Last November, the company settled civil claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.

  • Biogen Idec taps Sangamo for blood disorder drugs Biogen Idec taps Sangamo for blood disorder drugs

    Meanwhile, supportive therapies are also available, notably Novartis' Exjade (deferasirox) which was approved in the EU last year to manage iron overload in thalassaemia.

  • Novartis' Exjade gets EU approval for thalassaemia Novartis' Exjade gets EU approval for thalassaemia

    For the first time, Exjade will be available to thalassemia patients who are not regularly transfused but still suffer from the life-altering effects of excess iron," he added. ... Approval in thalassaemia adds to the peak sales potential for Exjade and

  • Novartis' net income up 15 per cent for Q2

    Successful launches included Exjade (deferasirox), which made $192m after receiving regulatory approvals in the US and Europe for the treatment of chronic iron overload, and Certican/Zortress (everolimus) which made $26m

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....